M. Korell

Effectiveness outcomes by treatment-free interval among patients receiving palbociclib plus endocrine therapy in HR+/HER2− advanced breast cancer in the real-world setting: Results from the PERFORM study.

Rupert Bartsch, M. Korell, G Pfeiler, Thomas Gabrysiak et autres

1061 Background: Combination of CDK4/6 inhibitors (CDK4/6i) plus endocrine therapy (ET) is first-line (1L) standard of care for patients (pts) with HR+/HER2- advanced breast cancer (ABC). Treatment-free interval (TFI) is an established prognostic factor in ABC. Shorter TFI is associated with more …

at, de, fr (code pays fourni par la source)

Fertility Preservation for Patients with Malignant Disease. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 015/082, May 2025)

Laura Lotz, Sabine Kliesch, Dunja Baston-Buest, Andreas Schüring et autres

Abstract Goal The aim of this official guideline, which was coordinated by the German Society of Gynaecology and Obstetrics (DGGG) together with the German Society of Urology (DGU) and the German Society of Reproductive Medicine (DGRM), is to provide consensus-based recommendations for …

de, at, ch, ee (code pays fourni par la source)

Real-World-Wirksamkeit von Palbociclib+endokriner Therapie in der Erstlinie und nachfolgenden Behandlungen bei Patienten mit HR+/HER2- fortgeschrittenem Brustkrebs: Zwischenergebnisse der PERFORM-Studie

Georg Pfeiler, Rupert Bartsch, M. Korell, Thomas Gabrysiak et autres

Einleitung Die Kombination aus CDK4/6-Inhibitoren (CDK4/6i) und endokriner Therapie (ET) ist Erstlinien-(1L) Standard bei Patient:innen mit HR+/HER2- fortgeschrittenem Brustkrebs (ABC). Die sich entwickelnde therapeutische Landschaft wirft neue Fragen zur optimalen Behandlung nach Versagen von CDK4/6i+ET auf. Real-World- (RW) Evidenz ergänzt klinische Studien …

at, de, gb (code pays fourni par la source)

PERFORM

Rupert Bartsch, M. Korell, Georg Pfeiler, Thomas Gabrysiak et autres

519P Real-world effectiveness of 1st line palbociclib + endocrine therapy and subsequent treatments in patients with HR+/HER2- advanced breast cancer: Interim results from the PERFORM study

Rupert Bartsch, M. Korell, G. Pfeiler, Thomas Gabrysiak et autres

at, de, it, cn, us, ca (code pays fourni par la source)

Abstract P4-07-20: Is Distance to Treating Oncologist a Potential Prognostic Real-World-Factor for Patients with HR+/HER2- Advanced Breast Cancer? Results from the Non-Interventional Study PERFORM

Michael P. Lux, Georg Pfeiler, M. Korell, Julia Radosa et autres

Abstract Background: Real-world evidence (RWE) is generated to explore the safety and effectiveness of approved agents in a broad real-world population in regionally specific health care structures. The distance to treating oncologist (DTO) is a rarely analyzed real-world factor of high interest. …

Differences in health-related Quality of Life in patients with or without progression on palbociclib therapy. Preliminary results from the Non-Interventional Study PERFORM

Vesna Bjelic‐Radisic, M. Korell, G Pfeiler, Thomas Gabrysiak et autres

Objective: CDK4/6-inhibitor+endocrine-therapy (ET) is standard first-line (1L) treatment for HR+/HER2- advanced breast cancer based upon demonstrated efficacy, safety, tolerability and quality of life (QoL) from randomized clinical trials (RCT). Real-world evidence is an important complement to RCTs. A highly relevant and rarely …

de, at (code pays fourni par la source)

Second pregnancy in China 5 years after ovarian tissue transplantation to prevent iatrogenic POI

Xiangyan Ruan, Juan Du, Fengyu Jin, Muqing Gu et autres

OBJECTIVE: This article reports the second live birth in China after frozen-thawed ovarian tissue transplantation to prevent iatrogenic premature ovarian insufficiency (POI). METHOD: A patient with aplastic anemia received ovarian tissue cryopreservation before hematopoietic stem cell transplantation, and four ovarian cortex strips …

cn, us, de (code pays fourni par la source)

Early Pregnancy Loss in the 1st Trimester

Matthias David, Nicolas von Ahsen, İbrahim Alkatout, Franz Bahlmann et autres

Abstract Purpose This guideline aims to improve and standardize the diagnostic and therapeutic approaches for different types of miscarriages, pregnancies of unclear localization, and ectopic pregnancies in the 1st trimester. Methods In accordance with the requirements for an S2k-guideline, this guideline was …

de, ch, at (code pays fourni par la source)

356P Real-world effectiveness in subgroups of palbociclib + endocrine therapy in HR+/HER2- ABC patients: Interim results of the PERFORM study

Georg Pfeiler, M. Korell, JC Radosa, Thomas Decker et autres

at, de (code pays fourni par la source)

Patient-reported outcomes (PROs) including treatment expectation and satisfaction in HR+/HER2- Advanced Breast Cancer patients treated: Real-world Results of the PERFORM study from interim analysis 3 (IA3)

Vesna Bjelic‐Radisic, M. Korell, G. Pfeiler, Julia Caroline Radosa et autres

Background: Endocrine therapy (ET)+CDK4/6 inhibitors are 1L standard-therapy in HR+/HER2- advanced breast cancer patients. Real-world insights into effectiveness and Quality of Life (QoL) are important and complementary to clinical trial data. Methods: The prospective, non-interventional PERFORM study aims to enroll 1,900 patients …

de, at (code pays fourni par la source)

209P Real-world effectiveness of palbociclib + endocrine therapy in HR+/HER2- advanced breast cancer patients: Interim results of the PERFORM study

M. Korell, Georg Pfeiler, JC Radosa, Thomas Decker et autres

Endocrine therapy (ET) + CDK4/6 inhibitors are first-line (1L) standard in patients (pts) with HR+/HER2- advanced breast cancer (ABC). High efficacy and good tolerability have been shown in randomized clinical trials. To support these findings and to obtain insights in the CDK4/6i …

de, at (code pays fourni par la source)